Associated Papers
The equilibrium between two quaternary assembly states determines the activity of SPOP and its cancer mutants.
Cuneo MJ et al.
Biorxiv : the Preprint Server for Biology, 2025
Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer.
Yao J et al.
Frontiers in Immunology, 2025
40519936 (PubMed )
Supplement: Table1.xlsx › SNV
Mass spectrometry-based targeted proteomics for analysis of protein mutations.
Lin TT et al.
Mass Spectrometry Reviews, 2023
SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis.
Gao K et al.
Cell Death and Differentiation, 2023
Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Shi Q et al.
Molecular Cancer, 2019
The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Yan Y et al.
Embo Molecular Medicine, 2019
SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
Ma J et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2018
Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Wang H et al.
Journal of Translational Medicine, 2017
Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
Jin X et al.
Plos Genetics, 2017
3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets.
Gao J et al.
Genome Medicine, 2017
Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.
Kim E et al.
Cancer Discovery, 2016
Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
Zhang P et al.
Human Mutation, 2014
Select a paper to view details